REGENXBIO sets investor event to discuss the sura-vec wet AMD program, providing clinical updates and specialist perspectives ahead of the anticipated 4Q 2026 pivotal data release.
Company announces investor event for sura-vec in wet AMD ahead of pivotal data readout expected in 4Q 2026, with no new financial or clinical results disclosed.
REGENXBIO Inc. announced an upcoming investor event focused on its sura-vec clinical program for wet age-related macular degeneration (wet AMD). The session will feature a comprehensive program overview and insights from retina specialists as the company prepares for a pivotal data readout expected in the fourth quarter of 2026.
The event focuses on providing a clinical program overview and expert perspectives regarding sura-vec, the company's treatment candidate for wet age-related macular degeneration.